Ipsen's Latest Update on CONTACT-02 Trial in Metastatic Castration-Resistant Prostate Cancer
Sunday, 15 September 2024, 06:52
Phase III Trial Highlights
The CONTACT-02 trial has been pivotal in assessing the efficacy of Cabometyx® (cabozantinib) when used alongside atezolizumab for patients with metastatic castration-resistant prostate cancer. Recent analyses reveal positive trends in overall survival rates.
Study Design
- Phase III clinical trial involving multiple sites.
- Focus on patient outcomes in terms of survival.
- Combination treatment of Cabometyx® and atezolizumab.
Key Findings
The trial demonstrates significant potential for combining therapies in improving patient prognosis:
- Improvement in Overall Survival Rates: Emerging data points towards enhanced survival outcomes.
- Positive Patient Response: Indicators suggest improved quality of life for participants.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.